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Received December 20, 2000; accepted January 9, 2001Last year the rotavirus (RV) field sustained a profound
surprise and setback when the first licensed RV vaccine
(Rotashield–Wyeth Ayert) was withdrawn from the market
because of its temporal association with very rare cases
of intestinal intussusception which mostly occurred in
the first week after administration of the first vaccine
dose [reviewed in Nakagomi (2000)]. The impact of the
RV vaccine on the total incidence of intussusception
(attributable risk of Rotashield vaccine) has not yet been
thoroughly evaluated but could be very small (Nakagomi,
2000). Nonetheless, given the reported strength of the
temporal association, it seems unlikely that this vaccine
will ever be reconsidered for widespread use in the
United States. Hence, the need for a new vaccine or
vaccines is great. Since the Rotashield vaccine also had
minor side effects (low-grade fever in children, primarily
after the first dose) (Vesikari et al., 1999) and induced
incomplete protection (Bresee et al., 1999; Conner et al.,
1996), the obstacles to the development of an ideal RV
vaccine are not trivial (Table 1). In this brief review, we
will address selected immunological problems associ-
ated with the development of a successful RV vaccine.
Studies in naturally infected children and in animals
have shown that intestinal antibodies are pivotal in pro-
tection from RV reinfection (Conner et al., 1996; Coulson
et al., 1992; Feng et al., 1994; Franco and Greenberg,
1999; Matson et al., 1993). As opposed to systemic mem-
ory antibody responses, antiviral intestinal IgA re-
sponses in people are generally of short duration (Coul-
son et al., 1992; Murphy, 1999) and this is one of the likely
explanations for the high rate of reinfection and disease
in young children and some adults (Conner et al., 1996;
Velazques et al., 1996). Because T-cell-independent B
cell responses are short lived, it is tempting to speculate1 To whom correspondence and reprint requests should be ad-
ressed.
153that, at least in the mouse model, the falling level of
memory B cells in the gut is related to the recent finding
that many of the IgA ASC of the intestines of mice are
antigen-specific T-cell-independent B1 cells (Macpher-
son et al., 2000). RV-specific intestinal IgA has been
shown to be produced in completely T-cell-deficient mice
(Franco and Greenberg, 1999) and this response ap-
pears to be functional. However, the role of the short-
lived T-cell-independent IgA response in immunocompe-
tent mice (and people) remains unknown.
In studies performed in day-care centers and or-
phanages where antibodies to RV have been mea-
sured very shortly before a RV outbreak, intestinal
and/or serum antibodies have correlated with protec-
tion against natural RV reinfection (Conner et al., 1996;
Matson et al., 1993). RV-specific antibodies (stool IgA
in particular) have also been correlated with protection
in some (Coulson et al., 1992) but not in all other
studies involving naturally infected as well as vacci-
nated children (Conner et al., 1996; Ward et al., 1997).
In general, serum antibody levels have correlated bet-
ter with protection following natural infection than fol-
lowing vaccination (Velazquez et al., 2000). Thus, at
present we do not have a precise and reliable marker
of protection induced by vaccination. This absence
has been an impediment to the development of new
RV vaccines since the only way of determining that a
vaccine is effective is with extensive and expensive
field trials (Conner et al., 1996; Ward et al., 1997). Fecal
antibody levels have been measured in a few vaccine
studies but have not correlated well with protection,
perhaps because they have not been measured at the
appropriate time or because of inherent technical
problems with the measurement of fecal IgA (Conner
et al., 1996). Since the technical difficulties in the
measurement of fecal IgA are not absolute as is evi-
denced by the studies of naturally infected children
(Coulson et al., 1992; Matson et al., 1993), future vac-
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154 MINIREVIEWcine studies should include more and better validated
measurements of RV-specific fecal IgA (Conner et al.,
1996).
RV-specific serum IgA has not provided a consistent
correlate of protection induced by vaccination (Ward et
al., 1997). In mice, heterologous (nonmurine) RVs, at
certain doses, can induce a systemic immune response
without inducing a substantial mucosal response (Feng
et al., 1994). In humans, up to 95% of the serum anti-RV
IgA is monomeric and thus likely of systemic origin. This
information provides a possible explanation for the exis-
tence of children who developed RV-specific serum IgA
after vaccination with the Rhesus vaccine but were not
protected. Presumably, in these cases, serum IgA was of
systemic origin and not locally effective. Another possi-
ble explanation for why the presence of RV-specific se-
rum IgA did not correlate with protection after vaccina-
tion is that the IgA antibodies induced by vaccination
have a different specificity than those induced by natural
infection. The lack of a clear correlation of serum-neu-
tralizing antibodies with protection in the vaccine studies
suggests that this could be the case (Ward et al., 1997).
On the other hand, effectively vaccinated children with
low levels of RV-specific serum IgA or neutralizing anti-
bodies could have been protected by alternative immune
T
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local humoral immunity is to study blood-circulating an-
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to those sites for local antibody secretion (Kantele, 1990).
In animal models, ELISPOT assays of blood-circulating
mononuclear cells have been clearly shown to provide
good correlates of protection and to reflect the numbers
and quality of the ASC in the intestine (Yuan et al., 1996).
In humans, blood-circulating ASC have been useful to
study the immunogenicity of RV vaccines (Isolauri et al.,
995), and their appearance has recently been shown to
orrelate with the presence of RV-specific IgA ASC in the
mall intestine of healthy children (Brown et al., 2000). It
remains to be seen if the quantification of B-cell ELIS-
POTs will yield a better surrogate marker of protection
induced by vaccination as has been suggested in stud-
ies with salmonella vaccines (Kantele, 1990). As opposed
to the ELISPOT assay which generally measures only
effector B cells, an alternative marker of protection in-
duced by RV vaccines or natural infection might be ob-
tained by the accurate measurement of the low levels of
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155MINIREVIEW(based on ELISPOT or flow cytometry) to study individual
memory B cells that express virus-specific surface inmu-
noglobulin and individual antigen-specific T cells are
now available (Kuklin et al., 2000, 2001).
Finally, although it is widely acknowledged that differ-
nces in the immune response between very young
hildren and adults exist, these differences have not
een well defined in general or for RV immunity in par-
icular. Most studies in this area have been based on
bservations in mice that cannot be directly extrapolated
o humans because they have a very different ontological
evelopment. Our lack of knowledge of how the immune
esponse of young children is generated or maintained
o a mucosal pathogen like RV is probably an important
mpediment in the development of optimal vaccine strat-
gies.
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